Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
MPX to Moderate Panel on “Pharmaceutical Cannabis in Canada”

19h globenewswire
TORONTO, Aug. 15, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE: MPX; OTC: MPXEF) today announced that Michael Arnkvarn, its Chief Marketing Officer and General Manager of Canadian Operations will be moderating a panel on Pharmaceutical Cannabis in Canada on Thursday, August 16, 2018.
MPXEF BCC CBICF

0
MPX Bioceutical Corporation Reports Financial Results for Its Fiscal Year 2018

2018-08-02 globenewswire
TORONTO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE: MPX; OTC: MPXEF) today reports financial results for its fiscal year ended March 31, 2018 and provides a general business update. All figures are presented in Canadian dollars.
MPXEF BCC CBICF

0
MPX Postpones Filing Date of 2018 Annual Statements

2018-07-30 globenewswire
TORONTO, July 30, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE: MPX; OTC: MPXEF) today announced the Company will postpone the filing of its fiscal 2018 financial statements as a result of accounting delays caused by the numerous acquisitions the Company closed during the fiscal year. Specifically, the Company and its auditors are still working to finalize reporting of the purchase price allocations in respect of those acquisitions.
MPXEF BCC CBICF

0
MPX Provides Additional and Updated Disclosures in Revised Management’s Discussion and Analysis

2018-07-25 globenewswire
TORONTO, July 25, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) announced that it has filed today a Revised and Restated Management’s Discussion and Analysis (the “Revised MD&A”) as at, and for, the three and nine month periods ended December 31, 2017.
MPXEF BCC CBICF

0
MPX Secures Final Approval to Open First Managed Dispensary in Maryland; Schedules Grand Opening for August 4th

2018-07-17 globenewswire
TORONTO, July 17, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) announced that final licensing approval was secured from the Maryland Medical Cannabis Commission (“MMCC”) on June 26, 2018 to open the first dispensary in the State of Maryland to be managed by S8 Management, LLC (“S8 Management”), An indirect wholly-owned subsidiary of the Corporation.
MPXEF BCC CBICF

0
MPX Responds to Arizona Court of Appeals Decision

2018-07-06 globenewswire
TORONTO, July 06, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) released the following statement in response to the decision by the Arizona Court of Appeals rendered on June 26, 2018 affirming the Yavapai County Superior Court decision convicting Rodney Christopher Jones of possessing a jar containing 0.05 ounces of “hashish.” The Company’s statements come after careful review, consultation with advisors and statements from the regulators.
MPXEF BCC CBICF

4
MPX Completes Acquisition of Canadian Licensed Producer

2018-06-11 globenewswire
TORONTO, June 11, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) is pleased to announce that it has successfully completed the acquisition of 100% of the issued and outstanding shares (the “Canveda Shares”) of 8423695 Canada Inc. operating as Canveda (“Canveda”), as previously announced on April 17, 2018. Canveda is a Licensed Producer under Health Canada’s Access to Cannabis for Medical Purposes Regulations having received its Cultivation License on June 12, 2017.
MPXEF BCC CBICF

4
MPX Bioceutical Corporation to Host Investor Conference Call on June 12, 2018

2018-06-07 globenewswire
TORONTO, June 07, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (CSE:MPX) (OTC:MPXEF) today announced that it will hold a conference call to update investors on the recently completed US$40 million convertible loan financing as well as providing an operational update to investors. The call will be hosted by W. Scott Boyes, Chairman, President and Chief Executive Officer of MPX, on Tuesday, June 12, at 11:00 a.
MPXEF BCC CBICF

4
MPX Appoints Robert Petch to the Board of Directors

2018-06-06 globenewswire
TORONTO, June 06, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) is pleased to announce that Robert Petch has joined the board of directors of MPX. Mr. Petch has over 30 years of experience in management, strategic planning and financial analysis. With experience on both the buy-side and sell-side of the investment market, Mr. Petch will be a valuable asset on the execution of MPX’s on-going strategy of growth in the North American cannabis industry.
MPXEF BCC CBICF

4
MPX Raises US$40 Million Secured Convertible Loan to Fund Capacity Development of MPX Assets and Acquisitions

2018-05-29 globenewswire
TORONTO, May 29, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) is pleased to announce that it has successfully completed a US$40,000,000 secured convertible original issue discount loan (the “Convertible Loan”) financing (the “Offering”) maturing on May 25, 2021 (the “Maturity Date”). While non-interest bearing, the Convertible Loan has been issued at a discount price of US$812.
MPXEF BCC CBICF

4
MPX to Present at the Planet MicroCap Showcase 2018 in Las Vegas, NV, April 24-26, 2018

2018-04-23 accesswire
TORONTO, ON / ACCESSWIRE / April 23, 2018 / MPX Bioceutical Corporation ("MPX" or the "Company") (CSE: MPX; OTCQB: MPXEF) announces that it will be participating in a panel discussion on ''What's Next for Cannabis Investors,'' on Tuesday, April 24, 2018, at 1:10 pm (PST) at the Planet MicroCap Showcase in Las Vegas, NV. The Company will also be presenting a corporate update at 9:00 am (PST) on Wednesday, April 25, 2018, in addition to conducting one-on-one meetings the morning of April 26, 2018.
MPXEF BCC CBICF

4
MPX Adds a Fourth Dispensary in Phoenix and Triples Capacity for MPX Concentrate Production in Arizona

2018-04-09 globenewswire
TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) is pleased to announce that the official opening of the its newest “Health for Life” medical marijuana dispensary in the Metropolitan Phoenix area, located at the junction of E. Main and Crimson in the suburb of Apache Junction. This brings the number of dispensaries under MPX management in Arizona’s Sun Valley to four.
MPXEF BCC CBICF

4
Mpx Enjoys Record Monthly Revenue of Cdn$5.2 Million in Arizona

2018-04-03 globenewswire
TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) has reported that its managed Arizona assets have recorded their best revenue month in March with sales of cannabis and cannabis concentrates hitting the US$4.0 (CDN$5.2) million mark for the first time.
MPXEF BCC CBICF

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 135372100